M945. Nonhepahinic Mucopolisacarid. In Vivo Studies(Humans)
It has been reported,in in vivo studies (doga, rabbita), that the antithrombotic protection of heparin is clearly related to AntiXa enhanced activity,than to a particular KCCT level(1)(2)In this work, 20 healthy individuals were studied. KCCT, TT, AntiXa (Denaon-Bonnar) deter minations were made. In vitro studies of M945 actiona on these tests, at different plasma concentrations of the drug (0.02-0.2UI/al) were performed.M945 waa then SC administered, 100UI/kg weight, and blood aamples collected each two houra, and KCCT, TT, AntiXa studied.In vitro samples showed no differences in KCCT, TT, and Anti Xa activity, that the ones expected when using heparin. In 16 humana, in post infusion studie s, it was seen that nearly no changea on KCCT or TT occured,vhile AntiAa waS enhanced in its activity, up to 90" (more than corresponding valuea for 0.2UI/al of heparin in plaamal.Further work with similar drugs to M945, should open the poasibility of safe antithrombotic treatments in patients with anticoagulant contraindications.1. Szwarcer E, Giuliani R, vIII World Congr Cardiol, Abatr, 1, 1159, pg 381, 19782. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent H, Elood, Vol 49, N82, 171, (feb), 1977